Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1186]

ESMO 2025: Prostate highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ESMO 2025: Prostate highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ESMO 2025: Renal highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ESMO 2025: Renal highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for...

Dr Scott Tagawa - Weill Cornell Medicine, New York, USA

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC ( Dr Scott Tagawa - Weill Cornell Medicine, New York, USA )

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher...

Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity ( Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada )

Durvalumab with BCG and maintenance therapy improves disease-free survival in...

Dr Maria De Santis - Charité University Hospital, Berlin, Germany

Durvalumab with BCG and maintenance therapy improves disease-free survival in high-risk NMIBC ( Dr Maria De Santis - Charité University Hospital, Berlin, Germany )

Perioperative enfortumab vedotin plus pembro improves survival and pCR in...

Prof Christof Vulsteke - Maria Middelares General Hospital, Ghent, Belgium

Perioperative enfortumab vedotin plus pembro improves survival and pCR in cisplatin-ineligible MIBC ( Prof Christof Vulsteke - Maria Middelares General Hospital, Ghent, Belgium )

Avelumab maintenance after reduced chemotherapy cycles improves QoL without...

Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain

Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC ( Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain )

MCED blood test demonstrates high specificity, strong predictive value, and...

Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection ( Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA )

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer

Prof Daniel Spratt - University Hospitals Cleveland Medical Center, Cleveland...

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer ( Prof Daniel Spratt - University Hospitals Cleveland Medical Center, Cleveland, USA )

ADT with PORT is a good treatment option for men with unfavourable intermediate...

Dr Mack Roach III - University of California San Francisco, San Francisco, USA

ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC ( Dr Mack Roach III - University of California San Francisco, San Francisco, USA )

Non-clear cell renal cell carcinoma: Management of papillary RCC

Prof Camillo Porta and Prof Laurence Albiges

Non-clear cell renal cell carcinoma: Management of papillary RCC ( Prof Camillo Porta and Prof Laurence Albiges )

Bladder cancer updates from the first half of 2025

Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone...

Bladder cancer updates from the first half of 2025 ( Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone and Dr Benjamin Pradere )

More from ecancer